Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total value of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total value of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock traded up $0.17 during mid-day trading on Wednesday, reaching $48.14. The stock had a trading volume of 588,235 shares, compared to its average volume of 434,867. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $48.94. The stock’s 50-day simple moving average is $41.28 and its 200-day simple moving average is $29.58. The firm has a market capitalization of $2.32 billion and a PE ratio of -2.30.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MAZE. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Wells Fargo & Company assumed coverage on Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target for the company. BTIG Research boosted their price objective on Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Guggenheim reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. Finally, Wedbush lifted their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and an average target price of $44.50.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds have recently modified their holdings of the company. CWM LLC bought a new position in shares of Maze Therapeutics in the second quarter valued at approximately $28,000. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics in the fourth quarter worth $39,000. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the period. Russell Investments Group Ltd. grew its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Maze Therapeutics during the 3rd quarter valued at $52,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.